In conclusion, PNO1 can be used as a diagnostic and prognostic biomarker of HCC, and knockout of PNO1 by CRISPR/Cas9 can be used for the treatment of HCC by targeting CSCs. The gene discussed is PNO1; the disease is hepatocellular carcinoma.